Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report

Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Oriol Mirallas, Francesca Filippi-Arriaga, Irene Hernandez Hernandez, Anton Aubanell, Anas Chaachou, Alejandro Garcia-Alvarez, Jorge Hernando, Elena Martínez-Saez, Betina Biagetti, Jaume Capdevila
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	capecitabine temozolomide aggressive pituitary tumors Nelson’s syndrome case report Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/1403f47cf247455c95993ccca85d6b87
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1403f47cf247455c95993ccca85d6b87
record_format	dspace
spelling	oai:doaj.org-article:1403f47cf247455c95993ccca85d6b872021-11-11T08:37:00ZAggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report1664-239210.3389/fendo.2021.731631https://doaj.org/article/1403f47cf247455c95993ccca85d6b872021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fendo.2021.731631/fullhttps://doaj.org/toc/1664-2392Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson’s syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide.Oriol MirallasFrancesca Filippi-ArriagaIrene Hernandez HernandezAnton AubanellAnas ChaachouAlejandro Garcia-AlvarezJorge HernandoElena Martínez-SaezBetina BiagettiJaume CapdevilaFrontiers Media S.A.articlecapecitabinetemozolomideaggressive pituitary tumorsNelson’s syndromecase reportDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENFrontiers in Endocrinology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	capecitabine temozolomide aggressive pituitary tumors Nelson’s syndrome case report Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	capecitabine temozolomide aggressive pituitary tumors Nelson’s syndrome case report Diseases of the endocrine glands. Clinical endocrinology RC648-665 Oriol Mirallas Francesca Filippi-Arriaga Irene Hernandez Hernandez Anton Aubanell Anas Chaachou Alejandro Garcia-Alvarez Jorge Hernando Elena Martínez-Saez Betina Biagetti Jaume Capdevila Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
description	Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson’s syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide.
format	article
author	Oriol Mirallas Francesca Filippi-Arriaga Irene Hernandez Hernandez Anton Aubanell Anas Chaachou Alejandro Garcia-Alvarez Jorge Hernando Elena Martínez-Saez Betina Biagetti Jaume Capdevila
author_facet	Oriol Mirallas Francesca Filippi-Arriaga Irene Hernandez Hernandez Anton Aubanell Anas Chaachou Alejandro Garcia-Alvarez Jorge Hernando Elena Martínez-Saez Betina Biagetti Jaume Capdevila
author_sort	Oriol Mirallas
title	Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
title_short	Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
title_full	Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
title_fullStr	Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
title_full_unstemmed	Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
title_sort	aggressive pituitary macroadenoma treated with capecitabine and temozolomide chemotherapy combination in a patient with nelson’s syndrome: a case report
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/1403f47cf247455c95993ccca85d6b87
work_keys_str_mv	AT oriolmirallas aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT francescafilippiarriaga aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT irenehernandezhernandez aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT antonaubanell aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT anaschaachou aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT alejandrogarciaalvarez aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT jorgehernando aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT elenamartinezsaez aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT betinabiagetti aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport AT jaumecapdevila aggressivepituitarymacroadenomatreatedwithcapecitabineandtemozolomidechemotherapycombinationinapatientwithnelsonssyndromeacasereport
_version_	1718439285046116352

Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report

Ejemplares similares